OS Therapies Incorporated (OSTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OS Therapies Incorporated (OSTX) has a cash flow conversion efficiency ratio of -1.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.71 Million) by net assets ($4.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of OS Therapies Incorporated to measure how much of total assets are equity-financed.
OS Therapies Incorporated - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how OS Therapies Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore OSTX operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
OS Therapies Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OS Therapies Incorporated ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Toplus Global Co Ltd
TWO:3522
|
0.184x |
|
Honmyue Enterprise Co Ltd
TW:1474
|
0.029x |
|
Gokul Refoils and Solvent Limited
NSE:GOKUL
|
0.080x |
|
Bever Holding NV
AS:BEVER
|
-0.009x |
|
EYG Gayrimenkul Yatirim Ortakligi A.S.
IS:EYGYO
|
0.020x |
|
MeVis Medical Solutions AG
XETRA:M3V
|
0.005x |
|
Oceanpal Inc
NASDAQ:OP
|
-0.007x |
|
Adaptimmune Therapeutics plc
F:473A
|
0.490x |
Annual Cash Flow Conversion Efficiency for OS Therapies Incorporated (2020–2024)
The table below shows the annual cash flow conversion efficiency of OS Therapies Incorporated from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see market value of OS Therapies Incorporated.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $811.49K | $-7.28 Million | -8.974x | -7267.42% |
| 2023-12-31 | $-24.02 Million | $-3.01 Million | 0.125x | -42.04% |
| 2022-12-31 | $-17.56 Million | $-3.79 Million | 0.216x | -43.82% |
| 2021-12-31 | $-11.45 Million | $-4.40 Million | 0.384x | +0.81% |
| 2020-12-31 | $-6.33 Billion | $-2.41 Billion | 0.381x | -- |
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide lin… Read more